ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.2
  1. ホーム
  2. /化合物

タクリン

Tacrine

HCID 1935
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
206658-92-6
標準SMILES
Nc1c2c(nc3ccccc13)CCCC2
InChIKey
YLJREFDVOIBQDA-UHFFFAOYSA-N
分子式
C13H14N2
平均分子量
198.26 g/mol
単同位体質量
198.11569846

概要

Tacrine is a member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor. It is a member of acridines and an aromatic amine. It is a conjugate base of a tacrine(1+).

名称と識別子

優先名称
Tacrine
IUPAC
1,2,3,4-tetrahydroacridin-9-amine
現地名
タクリン
英語名
1,2,3,4-Tetrahydro-9-acridinamine
分子式
C13H14N2
分子量
198.26

名称と別名

Tacrine1,2,3,4-tetrahydroacridin-9-amine321-64-2Tetrahydroaminacrine1,2,3,4-TETRAHYDRO-9-ACRIDINAMINETetrahydroaminoacridineTetrahydroaminocrinTetrahydroaminocrine9-amino-1,2,3,4-tetrahydroacridineTacrinaTacrinalTacrinum
名称をさらに表示
ロモタールテトラヒドロアミノアクリジン1,2,3,4-テトラヒドロ-9-アミノアクリジン9-アミノ-1,2,3,4-テトラヒドロアクリジンテトラヒドロアミノクリン1,2,3,4-テトラヒドロ-9-アクリジンアミン5,6,7,8-テトラヒドロアクリジン-9-アミンテトラヒドロアミナクリン1,2,3,4-テトラヒドロアクリジン-9-アミンタクリンTHATHATHAC01453acrinecs12602CS 12602AKOS 221-09
9-Acridinamine, 1,2,3,4-tetrahydro-1,2,3,4-Tetrahydro-9-aminoacridineDTXSID10372725-Amino-6,7,8,9-tetrahydroacridine4VX7YNB537DTXCID9017272CHEBI:459801,2,3,4-Tetrahydroaminoacridine

データベース識別子

CAS
206658-92-6、321-64-2
PubChem CID

物性

構造計算による物性補完中

XLogP
2.7
極性表面積
38.9 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
0
重原子数
15
形式電荷
0
複雑度
229

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 2 件

2.2

2.71

Solubility1.36e-01 g/L
Melting Point183.5 °C
Physical DescriptionSolid
Dissociation Constants · 4 件

9.8

9.8

9.85

9.95 (at 20 °C)

Collision Cross Section · 2 件

142.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID1037272]

148.62 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
183.5 ℃ · 183.5℃
沸点
325.59 °C · 325.59°C (rough estimate)
比重(密度)
0.9827 · 0.9827 (rough estimate)
屈折率

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P261, P262, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P316, P318, P319, P321, P330, P332+P317, P337+P317, P361+P364, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

危険有害性情報

Hazard Classes and Categories · 2 件

Acute Tox. 3 (100%)

Acute Tox. 3 (100%)

毒性情報

Treatment · 1 件

If the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally.

Health Effects · 1 件

Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Certain reproductive effects in fertility, growth, and development for males and females have been linked specifically to organophosphate pesticide exposure. Most of the research on reproductive effects has been conducted on farmers working with pesticides and insecticdes in rural areas. In females menstrual cycle disturbances, longer pregnancies, spontaneous abortions, stillbirths, and some developmental effects in offspring have been linked to organophosphate pesticide exposure. Prenatal exposure has been linked to impaired fetal growth and development. Neurotoxic effects have also been linked to poisoning with OP pesticides causing four neurotoxic effects in humans: cholinergic syndrome, intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP), and chronic organophosphate-induced neuropsychiatric disorder (COPIND). These syndromes result after acute and chronic exposure to OP pesticides.

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Protein Binding55%
Pharmacodynamics · 1 件

Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process.

Mechanism of Action · 1 件

The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine.

Biological Half-Life2 to 4 hours
Metabolism/Metabolites · 3 件

Hepatic. Cytochrome P450 1A2 is the principal isozyme involved in tacrine metabolism. The major metabolite, 1-hydroxy-tacrine (velnacrine), has central cholinergic activity.

Tacrine has known human metabolites that include 4- Hydroxytacrine, 2-Hydroxytacrine, 7-Hydroxytacrine, and N4-hydroxylamine.

Hepatic. Cytochrome P450 1A2 is the principal isozyme involved in tacrine metabolism. The major metabolite, 1-hydroxy-tacrine (velnacrine), has central cholinergic activity. Half Life: 2 to 4 hours

関連反応

26 件
反応記録を作成
HRID 195612 の反応式
HRID 195612反応物として
HRID 299421 の反応式
HRID 299421反応物として
HRID 359132 の反応式
HRID 359132反応物として
HRID 359133 の反応式
HRID 359133反応物として
HRID 456854 の反応式
HRID 456854反応物として
HRID 698506 の反応式
HRID 698506反応物として
HRID 748641 の反応式
HRID 748641反応物として
HRID 1146537 の反応式
HRID 1146537反応物として
前へ1 / 4 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
1935
DTXSID
DTXSID1037272
ChEMBL
CHEMBL1337960、CHEMBL95
ChEBI
CHEBI:45980
UNII
4VX7YNB537
EC Number
206-291-2、693-573-7
Nikkaji
J5.670G
1.44 · 1.4400 (estimate)
貯蔵温度
4 °C, · 4°C, away from moisture and light
溶解性
DMSO (Slightly), Methanol (Slightly)
外見
Solid
酸解離定数(Pka)
9 · 9+-.0.20(Predicted)
色
White to Pale Yellow
CAS データベース
321 · 321-64-2(CAS DataBase Reference)
Hepatotoxicity · 1 件

Strikingly, therapy with tacrine was associated with serum aminotransferase elevations in almost half of patients. These elevations usually arose within 6 to 8 weeks of starting therapy and rapidly resolved when therapy was stopped. Elevations above 3 times the upper limit of the normal range (ULN) occurred in 25%, above 10 times ULN in 6% and above 20 times ULN in 2% of patients. Accompanying elevations in alkaline phosphatase and bilirubin were rare, and the ALT abnormalities were usually asymptomatic and resolved rapidly when therapy was stopped or with dose reduction. Monitoring of serum aminotransferase levels during tacrine therapy was recommended, with dose modification for ALT elevations above 3 times the ULN and discontinuation if levels rose above 5 times the ULN. In prelicensure studies, no instances of clinically apparent acute liver injury with jaundice were reported. Subsequently, however, several cases of acute hepatocellular injury with jaundice attributed to tacrine were reported, generally arising within 2 to 8 weeks of starting therapy and usually resolving rapidly with discontinuation. Eosinophilia often accompanied the hepatic injury due to tacrine, but rash and fever were uncommon as were autoantibodies. Rechallenge often led to recurrence of the hepatic injury with a somewhat shorter latency but similar or milder course. In many patients, the serum aminotransferase elevations resolved even without drug discontinuation or dose modification. Nevertheless, fatal cases of liver injury attributed to tacrine were reported to the sponsor. Routine monitoring of serum aminotransferase levels for the first six months of therapy was recommended. However, the availability of other oral anticholinesterase inhibitors that are given only once or twice daily, do not require ALT monitoring and only rarely cause liver enzyme elevations has led to the withdrawal of tacrine from clinical use in the United States.

Exposure RoutesOral. Tacrine is rapidly absorbed. Absolute bioavailability of tacrine is approximately 17%.
Toxicity Summary · 1 件

Tacrine is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.

Signs and Symptoms · 1 件

Overdosage with cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

tacrine

Cognex®

Cholinergics

7

most-DILI-concern

安全データ

注意喚起語
危険
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H315
FDA Pharmacological Classification · 5 件

4VX7YNB537

TACRINE

Established Pharmacologic Class [EPC] - Cholinesterase Inhibitor

Mechanisms of Action [MoA] - Cholinesterase Inhibitors

Tacrine is a Cholinesterase Inhibitor. The mechanism of action of tacrine is as a Cholinesterase Inhibitor.

MeSH Pharmacological Classification · 3 件

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here.

Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms.

Absorption, Distribution and Excretion · 2 件

Tacrine is rapidly absorbed. Absolute bioavailability of tacrine is approximately 17%.

349 ± 193 L

Cellular LocationsCytoplasm

用途と製造

UsesFor the palliative treatment of mild to moderate dementia of the Alzheimer's type.
応用分野 · 2 件

説明In the 1950s, tacrine was used experimentally to reverse cholinergic coma in animals. In the 1960s, tacrine was used to reverse the effects of phencyclidine-like drugs. It was also marketed for many years as a respiratory stimulant. In 1993, the US Food and Drug Administration approved tacrine for the treatment of symptoms of mild to moderate Alzheimer’s disease.

使用The current use of tacrine is limited due to its poor oral bioavailability, the necessity for four daily doses, and serious side effects (including nausea, vomiting, dry mouth, indigestion, diarrhea, loss of appetite, urinary incontinence, collapse, convulsions, and hepatotoxicity). Currently, newer cholinesterase inhibitors (such as donepezil, rivastigmine, and galantamine) are preferred over tacrine.

上流・下流製品情報

上流原料

抱水クロラール2-アミノベンゾニトリルイサチン酢酸ナトリウムβ-イサトキシムグリシンZinc dichloride塩酸ヒドロキシルアミンシクロヘキサノンDexecadotril9(10H)-アクリジンイミン9,10-dihydroacridin-9-amine9-Acridinamine, tetradecahydro-